Home > Publications database > External validation of novel MRI-based models for prostate cancer prediction. > print

001     147733
005     20240229123029.0
024 7 _ |a 10.1111/bju.14958
|2 doi
024 7 _ |a pmid:31758738
|2 pmid
024 7 _ |a 1358-8672
|2 ISSN
024 7 _ |a 1464-4096
|2 ISSN
024 7 _ |a 1464-410X
|2 ISSN
024 7 _ |a altmetric:71094235
|2 altmetric
037 _ _ |a DKFZ-2019-02710
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Püllen, Lukas
|0 0000-0001-7505-1740
|b 0
245 _ _ |a External validation of novel MRI-based models for prostate cancer prediction.
260 _ _ |a Oxford
|c 2020
|b Wiley-Blackwell39962
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1582886811_31851
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Mar;125(3):407-416
520 _ _ |a To validate three novel risk models (RM) combining mpMRI and clinical parameters to predict significant prostate cancer (sPC) through an external cohort, including the recently updated European Randomised Study of Screening for PC (ERSPC) risk-calculator.We retrospectively analyzed 307 men who underwent mpMRI prior to transperineal ultrasound fusion biopsy between 10/2015 and 07/2018 at two German centers. mpMRI was rated by PI-RADSv2.0 and sPC was defined as ISUP Gleason grade group ≥2.The prediction performance of the three models (MRI-ERSPC-3/4, RM by Radtke et al. and RM by Distler et al.) were compared using ROC-curve-analyses with area under the curve (AUC), calibration curve analyses and decision curves to assess net-benefit.ROC-AUCs of the three novel models (MRI-ERSPC-3/4; Radtke's RM and Distler's RM were 0.82; 0.85 and 0.83, respectively). Calibration curve analyses showed the best intercept for MRI-ERSPC-3 and -4 of 0.35 and 0.76. Net benefit analyses indicated clear benefit of MRI-ERSPC-3/4-RM compared to the other two validated models. The MRI-ERSPC-RC-3/4 demonstrated a discrimination benefit for a risk threshold of up to 15% for sPC as compared to the other RMs.In our external validation of three novel prostate cancer risk calculators, which include mpMRI-findings in their models, head-to-head comparison of these models indicated that especially MRI-ERSPC-3/4 can help to reduce unnecessary biopsies.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
542 _ _ |i 2019-12-20
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
542 _ _ |i 2019-12-20
|2 Crossref
|u http://onlinelibrary.wiley.com/termsAndConditions#vor
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Radtke, Jan P
|0 P:(DE-He78)79897f8897ff77676549d9895258a0f2
|b 1
|u dkfz
700 1 _ |a Wiesenfarth, Manuel
|0 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
|b 2
|u dkfz
700 1 _ |a Roobol, Monique J
|b 3
700 1 _ |a Verbeek, Jan F M
|b 4
700 1 _ |a Wetter, Axel
|b 5
700 1 _ |a Guberina, Nika
|b 6
700 1 _ |a Pandey, Abhishek
|b 7
700 1 _ |a Hüttenbrink, Clemens
|b 8
700 1 _ |a Tschirdewahn, Stephan
|b 9
700 1 _ |a Pahernik, Sascha
|b 10
700 1 _ |a Hadaschik, Boris A
|b 11
700 1 _ |a Distler, Florian A
|b 12
773 1 8 |a 10.1111/bju.14958
|b Wiley
|d 2019-12-20
|n 3
|p 407-416
|3 journal-article
|2 Crossref
|t BJU International
|v 125
|y 2019
|x 1464-4096
773 _ _ |a 10.1111/bju.14958
|0 PERI:(DE-600)2019983-1
|n 3
|p 407-416
|t BJU international
|v 125
|y 2019
|x 1464-4096
909 C O |o oai:inrepo02.dkfz.de:147733
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)79897f8897ff77676549d9895258a0f2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)1042737c83ba70ec508bdd99f0096864
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|2 G:(DE-HGF)POF3-300
|v Addenda
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BJU INT : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1016/j.eururo.2017.02.026
|9 -- missing cx lookup --
|1 Moldovan
|p 250 -
|2 Crossref
|t Eur Urol
|v 72
|y 2017
999 C 5 |2 Crossref
|u Mottet N van den Bergh RCN Briers E et al. European Association of Urology Guidelines 2018
999 C 5 |1 Drost
|y 2019
|2 Crossref
|o Drost 2019
999 C 5 |a 10.1002/jmri.25372
|9 -- missing cx lookup --
|1 Greer
|p 579 -
|2 Crossref
|t J Magn Reson Imaging
|v 45
|y 2017
999 C 5 |a 10.1016/S0140-6736(16)32401-1
|9 -- missing cx lookup --
|1 Ahmed
|p 815 -
|2 Crossref
|t Lancet
|v 389
|y 2017
999 C 5 |a 10.1016/j.juro.2011.03.147
|9 -- missing cx lookup --
|1 Ahmed
|p 458 -
|2 Crossref
|t J Urol
|v 186
|y 2011
999 C 5 |a 10.1002/cncr.29874
|9 -- missing cx lookup --
|1 Filson
|p 884 -
|2 Crossref
|t Cancer
|v 122
|y 2016
999 C 5 |a 10.1016/j.urology.2015.07.038
|9 -- missing cx lookup --
|1 Mendhiratta
|p 1192 -
|2 Crossref
|t Urology
|v 86
|y 2015
999 C 5 |a 10.1016/j.urolonc.2014.09.013
|9 -- missing cx lookup --
|1 Panebianco
|p 17.e1 -
|2 Crossref
|t Urol Oncol
|v 33
|y 2015
999 C 5 |a 10.1016/j.eururo.2014.03.002
|9 -- missing cx lookup --
|1 Pokorny
|p 22 -
|2 Crossref
|t Eur Urol
|v 66
|y 2014
999 C 5 |a 10.1001/jama.2014.17942
|9 -- missing cx lookup --
|1 Siddiqui
|p 390 -
|2 Crossref
|t JAMA
|v 313
|y 2015
999 C 5 |a 10.1016/j.eururo.2014.10.026
|9 -- missing cx lookup --
|1 Valerio
|p 8 -
|2 Crossref
|t Eur Urol
|v 68
|y 2015
999 C 5 |a 10.1016/j.eururo.2018.11.023
|9 -- missing cx lookup --
|1 Leest
|p 570 -
|2 Crossref
|t Eur Urol
|v 75
|y 2019
999 C 5 |a 10.1016/S1470-2045(18)30569-2
|9 -- missing cx lookup --
|1 Rouvière
|p 100 -
|2 Crossref
|t Lancet Oncol
|v 20
|y 2019
999 C 5 |a 10.1056/NEJMoa1801993
|9 -- missing cx lookup --
|1 Kasivisvanathan
|p 1767 -
|2 Crossref
|t N Engl J Med
|v 378
|y 2018
999 C 5 |a 10.1111/bju.14809
|9 -- missing cx lookup --
|p 9 -
|2 Crossref
|t BJU Int
|v 124
|y 2019
999 C 5 |a 10.1016/j.euf.2016.07.007
|9 -- missing cx lookup --
|1 Gayet
|p 228 -
|2 Crossref
|t Eur Urol Focus
|v 4
|y 2018
999 C 5 |a 10.1093/annonc/mdu525
|9 -- missing cx lookup --
|1 Louie
|p 848 -
|2 Crossref
|t Ann Oncol
|v 26
|y 2015
999 C 5 |a 10.1007/s00345-011-0804-y
|9 -- missing cx lookup --
|1 Roobol
|p 149 -
|2 Crossref
|t World J Urol
|v 30
|y 2012
999 C 5 |a 10.1016/j.eururo.2009.08.025
|9 -- missing cx lookup --
|1 Roobol
|p 79 -
|2 Crossref
|t Eur. Urol
|v 57
|y 2010
999 C 5 |a 10.1111/j.1464-410X.2011.10207.x
|9 -- missing cx lookup --
|1 Trottier
|p E237 -
|2 Crossref
|t BJU Int.
|v 108
|y 2011
999 C 5 |a 10.1016/j.ejca.2012.02.002
|9 -- missing cx lookup --
|1 Vugt
|p 1809 -
|2 Crossref
|t Eur J Cancer
|v 48
|y 2012
999 C 5 |a 10.1111/j.1464-410X.2011.10611.x
|9 -- missing cx lookup --
|1 Vugt
|p 1480 -
|2 Crossref
|t BJU Int
|v 109
|y 2012
999 C 5 |a 10.1016/j.ejca.2010.11.012
|9 -- missing cx lookup --
|1 Vugt
|p 903 -
|2 Crossref
|t Eur J Cancer
|v 47
|y 2011
999 C 5 |a 10.1016/j.eururo.2011.11.029
|9 -- missing cx lookup --
|1 Zhu
|p 652 -
|2 Crossref
|t Eur Urol
|v 61
|y 2012
999 C 5 |a 10.1016/j.juro.2017.03.130
|9 -- missing cx lookup --
|1 Distler
|p 575 -
|2 Crossref
|t J Urol
|v 198
|y 2017
999 C 5 |a 10.1016/j.eururo.2017.03.039
|9 -- missing cx lookup --
|1 Radtke
|p 888 -
|2 Crossref
|t Eur Urol
|v 72
|y 2017
999 C 5 |a 10.1016/j.eururo.2018.07.031
|9 -- missing cx lookup --
|1 Alberts
|p 310 -
|2 Crossref
|t Eur Urol
|v 75
|y 2019
999 C 5 |a 10.1016/j.eururo.2015.12.052
|9 -- missing cx lookup --
|1 Radtke
|p 846 -
|2 Crossref
|t Eur Urol
|v 70
|y 2016
999 C 5 |a 10.1016/j.eururo.2015.08.052
|9 -- missing cx lookup --
|1 Weinreb
|p 16 -
|2 Crossref
|t Eur Urol
|v 69
|y 2016
999 C 5 |a 10.1111/bju.12132
|9 -- missing cx lookup --
|1 Kuru
|p 568 -
|2 Crossref
|t BJU Int
|v 112
|y 2013
999 C 5 |a 10.1016/j.juro.2011.07.102
|9 -- missing cx lookup --
|1 Hadaschik
|p 2214 -
|2 Crossref
|t J Urol
|v 186
|y 2011
999 C 5 |a 10.1097/01.pas.0000173646.99337.b1
|9 -- missing cx lookup --
|1 Epstein
|p 1228 -
|2 Crossref
|t Am J Surg Pathol
|v 29
|y 2005
999 C 5 |2 Crossref
|u SWOP - The Prostate Cancer Research Foundation, Oostvoorne Medical Source data - SWOP - The Prostate Cancer Research Foundation, Oostvoorne http://www.prostatecancer-riskcalculator.com/medical-source-data-2
999 C 5 |a 10.1177/0272989X06295361
|9 -- missing cx lookup --
|1 Vickers
|p 565 -
|2 Crossref
|t Med Decis Making
|v 26
|y 2006
999 C 5 |a 10.1200/JCO.2015.65.5654
|9 -- missing cx lookup --
|1 Kerr
|p 2534 -
|2 Crossref
|t J Clin Oncol
|v 34
|y 2016
999 C 5 |a 10.1016/j.eururo.2018.08.038
|9 -- missing cx lookup --
|1 Calster
|p 796 -
|2 Crossref
|t Eur Urol
|v 74
|y 2018
999 C 5 |a 10.1016/j.eururo.2013.03.030
|9 -- missing cx lookup --
|1 Moore
|p 544 -
|2 Crossref
|t Eur Urol
|v 64
|y 2013
999 C 5 |a 10.1001/jamaoncol.2017.5667
|9 -- missing cx lookup --
|1 Mehralivand
|p 678 -
|2 Crossref
|t JAMA Oncol
|v 4
|y 2018
999 C 5 |a 10.1111/bju.13814
|9 -- missing cx lookup --
|1 Leeuwen
|p 774 -
|2 Crossref
|t BJU Int
|v 120
|y 2017
999 C 5 |a 10.1016/j.eururo.2017.01.042
|9 -- missing cx lookup --
|1 Woo
|p 177 -
|2 Crossref
|t Eur Urol
|v 72
|y 2017

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21